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Abstract
The prediction of tumor behavior for patients with oral carcinomas remains a challenge for clinicians. The presence of lymph
node metastasis is the most important prognostic factor but it is limited in predicting local relapse or survival. This
highlights the need for identifying biomarkers that may effectively contribute to prediction of recurrence and tumor spread.
In this study, we used one- and two-dimensional gel electrophoresis, mass spectrometry and immunodetection methods to
analyze protein expression in oral squamous cell carcinomas. Using a refinement for classifying oral carcinomas in regard to
prognosis, we analyzed small but lymph node metastasis-positive versus large, lymph node metastasis-negative tumors in
order to contribute to the molecular characterization of subgroups with risk of dissemination. Specific protein patterns
favoring metastasis were observed in the ‘‘more-aggressive’’ group defined by the present study. This group displayed
upregulation of proteins involved in migration, adhesion, angiogenesis, cell cycle regulation, anti-apoptosis and epithelial to
mesenchymal transition, whereas the ‘‘less-aggressive’’ group was engaged in keratinocyte differentiation, epidermis
development, inflammation and immune response. Besides the identification of several proteins not yet described as
deregulated in oral carcinomas, the present study demonstrated for the first time the role of cofilin-1 in modulating cell
invasion in oral carcinomas.
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Introduction
Similar to other head and neck tumors, oral squamous cell
carcinomas (OSCCs) are heterogeneous with regard to anatomic
subsites, clinical presentation and outcome. They affect the
mucosa between the lip and the palate including oral tongue,
floor of the mouth, buccal mucosa, alveolar ridge and retromolar
trigone (International Classification of diseases/ICD, http://www.
who.int/classifications/icd/en/). Clinically, OSCCs may remain
locally invasive or be more aggressive and metastasize. Actually,
histologically similar lesions can follow significantly different
clinical courses and show different responses to therapy, probably
as a result of etiologic and molecular heterogeneity [1], as well as
of microenvironmental factors [2,3].
Most oral carcinomas metastasize to regional lymph nodes
instead of spreading to distant sites via hematogeneous routes. The
anatomic subsite and its microenvironment, including secreted
lymphangiogenic growth factors and lymphatic microvessel
density, may influence this dissemination pattern [4–6]. However,
to invade adjacent vessels, the tumor cells also need to change their
plasticity, from an epithelial to a more mesenchymal phenotype
[7,8], consequently with decreased epithelial adhesion, remodeling
of cytoskeleton and increased migratory features. Finally, the
success of the process depends on the survival of the neoplastic
cells in the vessels, escape from immune response, extravasation
and proliferation in lymph nodes [8].
OSCCs are frequently diagnosed at a late stage of the disease,
when the chances of cure are low and the treatments are more
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invasive. Unfortunately, even when the patients present with early-
stage disease, recurrence, local and distant metastasis and a second
primary tumor can occur. To predict the outcome of these
patients, TNM (tumor, node, metastasis) staging of the tumor,
especially the presence of regional lymph node metastasis, is still
the most important factor [9]. However, the clinical evaluation of
lymph node spread and relapse risks in patients with nonmetastatic
disease mainly depend on the tumor diameter and subsite. Because
the prognostic significance of these parameters is limited [10],
many histopathological markers have been investigated in the
recent decades: some are of little value in prognostication and
others show more consistent associations [11]. Several examples
may be mentioned, such as tumor thickness [12], histological
grading [13], apoptotic indices [14], DNA ploidy [15], microvas-
cular density [16,17] and vascular and perineural invasion [18].
Following the advances in high-throughput technologies,
numerous studies aiming to investigate molecular markers able
to predict behavior of OSCC have been published in the recent
years. Their results have shown a large number of gene and
protein expression patterns associated with progression and
outcome of head and neck cancer [1,19]. Cellular pathways
modulated by these proteins are frequently related to the cancer
hallmarks described by Hanahan and Weinberg [20,21], and
linked to proliferation, apoptosis, energy metabolism, immune
evasion, angiogenesis, invasion and metastasis processes. However,
most of these studies are based on a small sample size, which limits
the use of their data in clinical practice [11]. Particularly for
prognosticators of lymph node and distant metastasis, the
literature data are limited [1] but recent findings have suggested
that certain expression profiles can predict tumor dissemination or
be related to epithelial-to-mesenchymal transition [8,22].
In the present study, we used two-dimensional gel electropho-
resis (2-DE), mass spectrometry (MS) and immunodetection
methods to analyze protein expression in OSCCs and their
surgical margins. To maximize the coverage of proteins, we also
performed one-dimensional gel electrophoresis (1-DE) followed by
MS identification. Using a refinement for classifying oral
carcinomas in regard to prognosis, we analyzed small but already
lymph node metastasis-positive (N+) versus large, lymph node
metastasis-negative (N0) tumors. The rationale for this exploratory
classification is our limited ability to predict tumor behavior in
patients with OSCC based on only the presence of regional lymph
node metastasis. The purpose of the study is to enrich the
molecular characterization of OSCC subgroups with different
prognoses, especially those with risk of tumor dissemination.
Materials and Methods
Ethics Statement
The study protocol and the informed consent were approved by
the Committees on Ethics in Research of Heliopolis Hospital,
Arnaldo Vieira de Carvalho Cancer Institute, Clinics Hospital of
the Faculty of Medicine (University of Sa˜o Paulo) and by the
National Committee on Ethics in Research/CONEP (reference
number 1763/05, 18/05/2005). All patients provided their
written consent to participate in the study after being informed
about the research purposes.
Patients and Specimens
Two hundred fifty-two samples of primary OSCC and surgical
margin were obtained from a total of 144 patients. None of the
patients had received preoperative radiation or chemotherapy.
The samples were collected by the Head and Neck Genome
Project (GENCAPO), a collaborative consortium of research
groups from hospitals and universities in Sa˜o Paulo State, Brazil,
whose aim is to develop clinical, genetic and epidemiological
analysis of head and neck squamous cell carcinomas.
Immediately after surgery, the specimen was cut in two: one
part was snap-frozen and stored in liquid nitrogen and the other
part was fixed in formalin for routine histopathological examina-
tion. Analysis of hematoxylin and eosin-stained sections indicated
that each tumor sample contained at least 70% tumor cells and the
surgical margins were ‘‘tumor-free’’. The total set of samples was
derived from four oral subsites (C02= other and unspecified parts
of tongue; C03= gum; C04= floor of mouth; C06= other and
unspecified parts of mouth), according to the criteria established
by the World Health Organization (WHO) (http://apps.who.int/
classifications/apps/icd/icd10online/). Proteomic experiments
were carried out on samples from C02 and C04 subsites and
immunodetection analysis on samples from all subsites.
The tumors were classified by the TNM system [23]. Using a
refinement for classifying oral carcinomas in regard to prognosis,
small but lymph node metastasis-positive tumors (T1-2N+) at
diagnosis were considered potentially ‘‘more-aggressive’’ (MA),
and large, lymph node metastasis-negative ones (T2-3N0) were
considered ‘‘less-aggressive’’ (LA). A full description of the
clinicopathological data and techniques used to analyze the
samples is provided in Table S1.
Protein Extraction
Since the macrodissected clinical samples were small (from 0.3
cm3 to 0.5 cm3) and different fractions should be obtained from
the same sample for analysis on various platforms in a multicenter
study, proteins were extracted after RNA extraction by TRIzolH
Reagent (Invitrogen Corp., Carlsbad, CA, USA). Briefly, the
organic phase containing DNA and proteins was isolated, DNA
was precipitated with ethanol and, subsequently, the proteins of
the supernatant fraction were precipitated with isopropyl alcohol.
The pellets were then maintained for 10 min at 15 to 30uC,
sedimented at 12,000 g for 10 min at 4uC and washed three times
with 0.3 M guanidine hydrochloride in 95% ethanol. During each
wash step, the pellets were maintained in the washing solution for
20 min at room temperature and centrifuged at 7,500 g for 5 min
at 4uC. After the last wash, the pellets were vortexed in ethanol,
stored for 20 min at room temperature and centrifuged at 7,500 g
for 5 min at 4uC. The samples were dried for 5 to 10 min and
diluted in 1% sodium dodecyl sulphate (SDS) at 50uC. After
centrifugation at 10,000 g for 10 min at 4uC, the supernatants
were recovered and protein quantification was performed using
the detergent-compatible BCATM Protein Assay Kit (Pierce
Biotechnology, Rockford, IL, USA). All protein samples were
stored in aliquots at 280uC until analysis.
To minimize individual differences and to enable multiple
analyses of samples with a limited amount of proteins, one- and
two-dimensional gel electrophoresis were performed using pooled
samples grouped according to anatomic subsites and TNM system.
In total, 51 individual samples (28 tumors and 23 surgical margins)
from smoking patients older than 40 years were combined in pools
of tumors or surgical margins.
The pools were prepared by mixing equal amounts of protein
from each sample, resulting in a total of 100 and 1500 mg per pool
for 1-DE and 2-DE gels, respectively. A description of all the pools
is presented in Table S2. The flowchart of sample preparations
and analysis is shown in Figure 1.
One-dimensional Gel Electrophoresis (1-DE)
Protein pools of small N+ tumors and of large N0 tumors, and
one protein pool of their surgical margins were separated in one-
Protein Profile of Oral Carcinomas
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dimensional 12% resolving/5% stacking SDS-polyacrylamide gel
(SDS-PAGE). In total, 16 samples (10 tumor and 6 surgical margin
samples from 11 patients) were analyzed.
Briefly, the proteins were denatured at 98uC for 10 min in 5X
loading buffer with dithiothreitol (DTT) and 100 mg of each pool
were loaded into the wells. SDS-PAGE was carried out in a
vertical polyacrylamide gel system (SE 400 Vertical Unit, GE
Healthcare, Uppsala, Sweden) at 130 V. Molecular mass was
estimated using low molecular weight standard proteins of 14.4–
97 kDa (LMW Calibration Kit for SDS Electrophoresis, GE
Healthcare). Proteins were detected by Coomassie Brilliant Blue
staining. Each gel lane (from 14.4 to 97 kDa) was cut into 21 slices
of approximately equal size. The slices were destained, dehydrated
and digested with trypsin (Promega Corp., Madison, WI, USA).
Two-dimensional Gel Electrophoresis (2-DE)
In a similar way, protein pools of small N+ tumors and of large
N0 tumors, and protein pools of their surgical margins were
analyzed by 2-DE according to the protocol previously described
by de Marqui et al. [24] with modifications. In total, 36 samples (19
tumor and 17 surgical margin samples from 23 patients) were
analyzed.
Proteins were precipitated using ice-cold 100% acetone and
resuspended in rehydration solution (8 M urea, 2% w/v CHAPS
detergent, 0.3% w/v DTT, 0.5% v/v IPG buffer pH 3–10,
bromophenol blue trace) to a final volume of 250 mL before loaded
onto immobilized 13 cm linear pH gradient (IPG) strips (pH 3–10,
GE Healthcare). Isoelectric focusing (IEF) was performed for a
total of 26,500 Vh at 20uC and 50 mA/strip, using an Ettan
IPGphor Isoelectric Focusing (GE Healthcare).
IPG strips were equilibrated for 15 min in equilibration solution
[6 M urea, 50 mM Tris-HCl pH 8.8, 30% v/v glycerol (87% v/
v), 2% w/v SDS, bromophenol blue trace] containing 1% w/v
DTT, followed by incubation for 15 min in the same solution
containing 2.5% w/v iodoacetamide instead of DTT. IPG strips
were sealed on top of 12.5% SDS-polyacrylamide gels using 0.5%
w/v low-melting agarose in SDS running buffer with bromophe-
nol blue. Electrophoresis was performed at 15 mA per gel for
30 min at room temperature, followed by 30 mA per gel for 3–
5 h, in a Hoefer SE 600 Ruby system (GE Healthcare). All
samples were run in duplicate or triplicate to guarantee
reproducibility. The LMW Calibration Kit was used as a protein
standard.
Gels were Coomassie Blue-stained, scanned using an ImageS-
canner (GE Healthcare) and the images were analyzed using the
ImageMaster 2D Platinum software, version 6.0 (GE Healthcare)
for spot detection, quantification, and comparative and statistical
analysis. Basically, tumor and surgical margin groups or tumor
stage groups were created and the gels were matched to a
reference gel. The spot quantification for each gel was based on
the relative volume (percent volume), i.e. the volume of each spot
divided by the total volume over the whole image. Differential
analysis of images was performed by matching spots from two gels
of each group (‘‘more-aggressive’’ and ‘‘less-aggressive’’ tumors
Figure 1. Flowchart of sample preparation and analysis. Tu = tumor; SM = surgical margin; MA or more-aggressive = T1-2N+; LA or less-
aggressive = T2-3N0; TMA = tissue microarray; FFPE = formalin-fixed, paraffin-embedded; 1-DE = one-dimensional gel electrophoresis; 2-DE = two-
dimensional gel electrophoresis; LC = liquid chromatography; MALDI = matrix assisted laser desorption ionization; MS/MS = tandem mass
spectrometry; WB = Western blot; IH = immunohistochemistry; IF = immunofluorescence; siRNA = small interfering RNA.
doi:10.1371/journal.pone.0050517.g001
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and their surgical margins). The data obtained were evaluated
statistically using the Student’s t-test. Statistical significance was set
at p,0.05.
Mass Spectrometry (MS), Protein Identification and
Annotation
Bands from 1-DE gel were excised, reduced, alkylated and
submitted to in-gel digestion with trypsin [25]. An aliquot (4.5 mL)
of the resulting peptide mixture was separated by C18
(100 mm6100 mm) RP-nanoUPLC (nanoAcquity, Waters Corp.,
Milford, MA, USA) coupled with a Q-Tof Ultima mass
spectrometer (Waters) with nano-electrospray source at a flow
rate of 0.6 mL/min. The gradient was 2–90% acetonitrile (ACN)
in 0.1% formic acid over 45 min. The instrument was operated in
the ‘‘top three’’ mode, in which one MS spectrum is acquired
followed by MS/MS of the top three most-intense peaks detected.
The spectra were acquired using the MassLynx software version
4.1 (Waters) and the raw data files were converted to a peak list
format (mgf) by the Mascot Distiller software, version 2.2.1.0, 2008
(Matrix Science Ltd., London, UK).
The search results of 1-D gel electrophoresis were exported to
Scaffold Q+ software (version 3_00_03, Proteome Software Inc.,
Portland, OR, USA) and visualized using a filter as described by
Escalante et al. [26] and Eming et al. [27]. The protein
identification probability was .95%, one minimum peptide, and
95% of peptide probability. Briefly, proteins from the 21 gel slices
from each pool were grouped in three categories: more-aggressive
or less-aggressive tumors or surgical margins. As proposed by
Escalante et al. [26], relative quantification was obtained by the
quantitative value, which normalizes the spectral counts across the
experiment. This value represents an average total of nongrouped
spectral counts for a protein divided by the total nongrouping
spectral counts for the mass spectral runs from the gel slices from
each lane, which allows for a relative quantitative comparison of a
specific protein among samples. The normalized spectral counts
were obtained for each protein and the proteins with a fold change
of at least 1.5 were considered with differential abundance
between the categories. Fold change was calculated using the
statistical tests of Scaffold Q+ software (according to [28]).
Differentially expressed protein spots from 2-DE gels were
excised and also digested with trypsin [24]. Peptide digest were
mixed with matrix solution (10 mg/mL a-cyano-4-hydroxycin-
namic acid, 0.1% v/v trifluoroacetic acid/TFA in 50% v/v ACN)
in a 1:1 (v:v) ratio, spotted on a stainless steel sample plate and air
dried. Mass determinations were performed on a MALDI TOF-
TOF (Matrix Assisted Laser Desorption Ionization - Time of
Flight - Time of Flight) 4700 Proteomics Analyzer (Applied
Biosystems, Foster City, CA, USA) or a MALDI Q-TOF (Matrix
Assisted Laser Desorption Ionization - Quadrupole Ion Trap -
Time of Flight) Premier (Waters). Each sample was run in
triplicate. For protein identification, the data were searched
against a non-redundant protein Homo sapiens database (NCBI nr
2009.07.20, 9,298,190 sequences) using a MASCOT engine
version 2.0 (Matrix Science Ltd.), with carbamidomethylation of
cysteine as fixed modification, oxidation of methionine as variable
modification, one trypsin missed cleavage and a tolerance of 1 or
0.1 Da for both precursor and fragment ions.
Gene Ontology (GO) annotation (http://www.geneontology.
org/) was used to assign biological process terms for differentially
expressed proteins. To analyze biological functions, proteins with
altered expression profiles were imported into Ingenuity Pathway
Analysis Tool (IPA Tool, IngenuityHSystems, Redwood City, CA,
USA).
Validation Experiments
Complementary methodologies were performed to validate the
proteomic findings. The selection of proteins for validation
experiments was carried out after an extensive literature analysis.
The following criteria were used: (i) potential involvement in
cancer development or a yet unclear role in OSCC tumorigenesis,
(ii) expression pattern suggestive of a role in aggressive OSSC
behavior. Using these criteria as guidelines, one protein overex-
pressed in tumors and related to an invasive phenotype was
selected (cofilin-1). A known marker of head and neck squamous
cell carcinomas with a pronounced underexpression in tumors and
previously associated with malignant progression (keratin 4) was
also selected to validate our strategy.
Western blot. A subset of 49 samples (24 tumors and 25
surgical margins) from 30 patients was analyzed by Western blot.
The antibodies used were mouse monoclonal antibody anti-keratin
4 (6B10, sc-52321, Santa Cruz Biotechnology, Santa Cruz, CA,
USA) diluted 1:500, mouse monoclonal anti-a-tubulin (TU-02, sc-
8035, Santa Cruz Biotechnology) diluted 1:500 and mouse
monoclonal anti-b-actin (AC-15, A1978, Sigma-Aldrich, Saint
Louis, MO, USA) diluted 1:5000. Protein samples (9 mg) were
separated by SDS-PAGE (12% resolving gel with 5% stacking gel)
at 130 V for 60 min (Mini-Protean 3 Cell Electrophoresis System,
BioRad, Hercules, CA, USA), in denaturing conditions. The
molecular weight ladders used were the PageRulerTM Prestained
Protein Ladder (SM0671, Fermentas Life Sciences, Burlington,
ON, Canada) and the See Blue Plus2 Pre-Stained Standard
(Invitrogen).
The proteins were transferred (325 mA for 70 min) to
polyvinylidene difluoride/PVDF membranes (Immobilon-P, Milli-
pore Corp., Billerica, MA, USA) using transfer buffer (25 mM
Tris, 0.2 M glycine, 20% v/v methanol) and the Mini Trans-Blot
Electrophoretic Transfer Cell (BioRad). The membranes were
submitted to chromogenic staining using the Western Breeze
Immunodetection Kit (Invitrogen), according to the manufactur-
er’s protocol. The blots were analyzed using Gel Logic HP 2200
imaging system (Carestream Health Inc/Kodak Health Group,
Rochester, NY, USA).
Immunohistochemistry. For immunohistochemical analy-
sis, two tissue microarray (TMA) slides from 71 primary OSCC
samples, 12 tissue slides containing archival formalin-fixed,
paraffin-embedded tissue (FFPE) sections of OSCC samples, 69
tissue slides containing FFPE sections of paired surgical margins,
and frozen sections from 5 cases (4 tumors and 5 surgical margins)
were used (Table S1). In TMA, two representative tumor areas of
each case were selected from a hematoxylin- and eosin-stained
section of a donor block. Two cylinders per patient (diameter of
1 mm each) were punched out and arrayed in a recipient paraffin
block using an arraying device (Beecher Instruments, Silver
Spring, MD, USA). Therefore, each tissue microarray contained
142 cores of tumor samples.
Cofilin-1 and keratin 4 immunohistochemical analyses of TMA
or FFPE samples was performed by a pathologist using conven-
tional protocols. Briefly, after deparaffinization in xylene and
rehydration in graded ethanol, antigen epitope retrieval was
performed using 10 mM citrate buffer, pH 6.0 in a vapor cooker.
Endogenous peroxidase activity was blocked with 3% hydrogen
peroxide for 15 min. Rabbit monoclonal anti-cofilin (D3F9-XP,
5175, Cell Signaling, Boston, MA, USA), rabbit polyclonal anti-
cofilin (phospho S3) (ab12866, Abcam, Cambridge, UK) diluted
1:400 and 1:300, respectively, and mouse monoclonal antibody
anti-keratin 4 (sc-52321, Santa Cruz Biotechnology) diluted 1:200,
were incubated overnight at 8uC followed by addition of the
secondary antibody and streptavidin-biotin peroxidase (LSAB+,
Protein Profile of Oral Carcinomas
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K0690, Dako, Carpinteria, CA, USA) or performed according to
standard protocols using the AdvanceTM HRP Detection kit
(K4068, Dako). Color of reaction product was developed by 3,39-
diaminobenzidine (DAB, Dako) and counterstaining was per-
formed with Harris hematoxylin.
The primary antibody was omitted for negative controls. The
extent of immunoreactivity (R) for cofilin-1 was semiquantitatively
graded as 0 (,10% of immunoreactive cells), score 1 (10–25% of
immunoreactive cells), score 2 (25–50% of immunoreactive cells),
score 3 (.50% of immunoreactive cells). For keratin 4, R was
graded as 0 (,5%), score 1 (5–10%), score 2 (11–50%), score 3
(51–75%) and score 4 (.75%). The staining intensity was
evaluated as negative (0), mild (1), moderate (2) and intense (3).
Cofilin-1 immunohistochemical analyses of frozen tissue sam-
ples were also performed using the streptavidin-biotin peroxidase
complex method. Tissue sections from stored frozen samples were
first stained with toluidine blue and reanalyzed to confirm the
presence of tumor cells or normal epithelium. Five-mm-thick
cryostat sections were then mounted on silane-coated glass slides,
immersed in cold methanol for 15 min, rinsed 3 times with
phosphate-buffered saline (PBS) for 2 min, followed by the
treatment with 3% hydrogen peroxide. The slides were treated
with a solution of 1% bovine serum albumin (BSA) in PBS for 1 h
and then incubated for 16 h at 4uC with either rabbit monoclonal
anti-cofilin (D3F9-XP, 5175, Cell Signaling) diluted 1:200 or with
rabbit polyclonal anti-cofilin (phospho S3) (ab12866, Abcam)
diluted 1:200. Subsequent incubations were performed with the
secondary antibody and streptavidin-biotin peroxidase (LSAB+,
K0690, Dako), developed with DAB and counterstained with
Mayer hematoxylin.
Immunofluorescence. The SCC-9 cell line (ATCC, Ma-
nassas, VA, USA), which is derived from a squamous cell
carcinoma of the tongue, was grown in a 1:1 mixture of
Dulbecco’s Modified Eagle’s Medium (DMEM, Invitrogen) and
Ham’s F12 Medium (DMEM/F12, Invitrogen) supplemented with
10% fetal bovine serum (FBS), 400 ng/ml hydrocortisone (Sigma-
Aldrich) and antibiotic/antimycotic (Sigma-Aldrich). After 24 h,
the cells were fixed with cold methanol for 15 min at room
temperature and rinsed 3 times with PBS for 2 min. Cells were
then treated with a solution of 1% BSA in PBS for 1 h and
incubated for 1 h at 25uC with rabbit polyclonal anti-cofilin
(phospho S3) (ab12866; Abcam) diluted 1:100, rinsed 3 times with
PBS and then incubated for 1 h at 25uC with the secondary
antibody donkey anti-rabbit IgG conjugated to Alexa Fluor 488
(A21206, Invitrogen) diluted 1:1000 for 1 h at 25uC. Nuclei were
stained with 49,6-diamidino-2-phenylindol (DAPI). Coverslips
were mounted with fluorescent mounting medium (S3023, Dako).
Invasion assay. The effect of cofilin-1 on tumor cell invasion
was determined by gene silencing with interference RNA (siRNA)
and Boyden chamber assay. The assay was carried out using the
SCC-9 and CAL 27 (ATCC) cell lines, the latter derived from a
poorly differentiated squamous cell carcinoma at the middle of the
tongue.
The cells were seeded in a 12-well plate (16105 cells/well):
SCC-9 cells were cultured overnight in 1:1 mixture of DMEM and
DMEM/F12 and CAL 27 cells were cultured overnight in
DMEM. Both media were supplemented with 10% FBS, 400 ng/
ml hydrocortisone and antibiotic/antimycotic.
Three siRNA duplex sequences against cofilin-1 (NM_005507,
siCofilin I: 187697918, II: 87697919 and III: 87697920, 20 nM)
and a negative control siRNA (Integrated DNA Technologies,
Coralville, IA, USA) were transfected into cells using Hyperfect
reagent (Qiagen, Germantown, MD, USA), according to the
manufacturer’s protocol. Knockdown efficiency was confirmed on
the protein level using Western blot analysis and immunofluores-
cence staining. The antibodies used were rabbit monoclonal anti-
cofilin (D3F9-XP, 5175, Cell Signaling) diluted 1:1000, rabbit
polyclonal anti-cofilin (phospho S3) (ab12866, Abcam) diluted
1:1000 and mouse monoclonal anti-a-tubulin (sc-8035, Santa
Cruz Biotechnology) diluted 1:500.
Invasion assay was performed using a Boyden chamber with a
polycarbonate filter (8 mm pore size) coated with Matrigel (10 mg/
ml). The cells (16105 suspended in 0.5 mL of serum-free DMEM/
F12) were seeded into the upper chamber. The bottom chamber
contained medium with 10% FBS. After 72 h of incubation, the
nonmigrated cells on the upper surface of the filter were carefully
removed. Cells that migrated to the bottom side of the filter were
fixed, stained and counted in 10 fields per well at 6200
magnification. The experiments were repeated three times.
Results
Patient Characteristics
Of the 144 patients with oral carcinomas included in the present
study, 119 (82.6%) were male and 25 (17.4%) female, most were
older than 50 years (56.1610.1 years), with a history of alcohol
(84.7%) and tobacco (93.1%) abuse. Eighty-two (56.9%) had N+
and 62 (43.1%) had N0 carcinomas: 22.2% (32/144) of tumors
were classified as ‘‘more-aggressive’’ (T1-2N+), 32% (46/144) as
‘‘less-aggressive’’ (T2-3N0), and 45.8% (66/144) as other groups
(Table S1).
Association with Tumor Development
The 1-DE results validated by Scaffold software allowed the
identification of 217 differentially expressed proteins ($1.5-fold
change) between tumors and surgical margins, with over 95%
confidence (as per the Scaffold algorithm, at least one unique
peptide per protein). Using these parameters the false discovery
rate (FDR) for protein identification was 0.2% (Table S3). The 2-
DE analysis revealed 29 differentially expressed proteins between
tumor and margin samples (Student’s t test p,0.05), most also
found by 1-DE approach (except actin cytoplasmic 2, carbonic
anhydrase 3, myoglobin, myosin light chain 3, superoxide
dismutase [Cu-Zn] and troponin T slow skeletal muscle), and
with an identical or similar expression pattern. Observed and
estimated molecular weight (MW) and isoelectric point (pI) were
similar, reinforcing the validity of the results (Table S4, Figures
S1–S2).
In summary, after the removal of redundancy, both approaches
led to the identification of 223 differentially expressed proteins.
Among the overexpressed proteins in cancer samples, many are
involved in glycolysis (a–enolase, glucose-6-phosphate isomerase
and triosephosphate isomerase 1), cell proliferation (40S ribosomal
protein S9, tenascin), anti-apoptosis (cathepsin D, cofilin-1, heat
shock protein b1, stratifin, voltage-dependent anion-selective
channel protein 1), signaling (14-3-3 protein b/a, 40S ribosomal
protein S6, collagen a-1 I, galectin-1, heat shock protein b1, Ras-related
protein Rap-1A, stratifin), adhesion (galectin-1, periostin, Ras-related
protein Rap-1A), migration (collagen a-1 I, myosin 9, prelamin-A/
C), cytoskeleton organization (desmin, myosin 9, profilin-1),
angiogenesis (ATP synthase b, myosin-9), immune response or
inflammation (60 kDa heat shock protein, glutathione S-transfer-
ase P, protein S100-A9), and response to stimulus (endoplasmin,
profilin-1).
Differential expression was also observed for proteins involved
in keratinocyte or epithelial cell differentiation and epidermis
development. Overexpression of desmoplakin, stratifin and
keratins typical of proliferative basal cells (keratins 5 and 14) and
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keratinizing oral mucosal epithelia (keratin 6A and 16) was
detected in tumor samples, whereas surgical margins exhibited
consistently high levels of a keratin characteristic of suprabasal
layers of oral nonkeratinizing epithelia (keratin 4).
Association with Aggressive Phenotype
Patients with ‘‘more-aggressive’’ (MA) and ‘‘less-aggressive’’
(LA) tumors showed a similar gender, age ratio and tumor subsite
distribution. The ‘‘more-aggressive’’ group exhibited a tendency
toward a younger age at diagnosis, but nonsignificantly (Chi-
square = 2.4576; p = 0.1170).
With respect to the protein profiles, MA and LA tumors
revealed fewer differences (but not less important) than were found
between tumor and surgical margins: 133 differentially expressed
proteins were identified by 1-DE (Table S3) and 12 by 2-DE
(Student’s t test p,0.05; Table S4, Figure S3).
The ‘‘less-aggressive’’ group expressed higher levels of proteins
involved in keratinocyte differentiation/epidermis development
(cystatin-A, desmoplakin, keratin 9, nucleoside diphosphate kinase
B and protein S100-A7) and inflammation/immune response
(high mobility group protein B1 and protein S100-A7). As
expected, the ‘‘more-aggressive’’ group showed a distinct pattern,
with higher expression of proteins involved in metastasis-related
processes, including migration (myosin-9), adhesion (a-actinin-1
and periostin), angiogenesis (ATP synthase b and myosin-9), cell
cycle (heat shock protein HSP90-a, septin-2, stathmin), anti-
apoptosis (60 kDa heat shock protein) and positive regulation of
epithelial to mesenchymal transition (collagen a-1(XII) chain).
Remarkable differences between MA and LA tumors were
observed in relation to proteins associated with cytoskeleton
organization (desmin, keratin 8, septin-2) and cofilin pathway
(actin-related protein 2/3 subunit 2 or ARP2/3, adenylyl cyclase-
associated protein 1 or CAP1, cofilin-1, F-actin-capping protein a-
1 or CAPZA1, HSP 90-a, tropomyosin a-3 isoform 4).
Validation of Upregulation of Cofilin-1 and
Downregulation of Keratin 4 by Immunodetection Assays
Immunoreactivity for total cofilin-1, an actin regulatory protein
essential for directed cell migration in many cell types, was high
(80/81) in tumor samples (independently of TNM) and mostly
localized in the cytoplasm (Figure 2C), whereas phospho-cofilin (p-
cofilin) staining was decreased or negative (7/11) and localized in
both nuclei and cytoplasm (Figure 2D). In surgical margins, the
intensity of total cofilin staining was apparently weaker than in
tumors and immunoreactivity was negative in the basal cell layers
of some (3/13) samples (Figure 2A). Staining for total cofilin
predominated in the cytoplasm and for p-cofilin in the nuclei of
normal cells (Figure 2A, B). No correlation between the percentage
of cofilin or p-cofilin stained cells and clinicopathologic factors was
observed.
Confirming what was observed in 1-DE and 2-DE, keratin 4
immunodetection experiments showed consistent differences in
expression in tumor samples compared with the surgical margins.
In Western blotting, keratin 4 was negative (18/24) or showed low
levels (3/24) in oral carcinomas and positive in most surgical
margins (23/25) (Figure 3D–E).
The immunohistochemical analysis revealed keratin 4 expres-
sion in superficial layers of non-tumoral epithelium (margin) with
intense positivity in stratum corneum (Figure 3A). Of the 65
surgical margins analyzed, 11 were keratin 4 negative indepen-
dently of TNM: four with normal epithelium (4/33), two with
hyperplasia (2/27) and five with dysplasia (5/5). Both patients with
hyperplastic mucosa had a local recurrence 3 months or 3 years
after surgery. Three cases showing dysplasia had a tumor relapse
at the original site 3 to 10 months after surgery, and another
developed a distant metastasis. Interestingly, among the patients
exhibiting keratin 4-negative margins, two had a local recurrence
2 to 3 years after surgery and radiotherapy and also a distant
metastasis; the other two patients developed a second primary
tumor at the same anatomical site or a distant metastasis. Briefly,
the frequency of recurrence, metastasis or a second primary tumor
at the same site was 90.9% (10/11) in patients with keratin 4-
negative margins in contrast to 51.8% (28/54) of the patients with
keratin 4-positive margins (Fisher’s exact test; p = 0.0197).
Complete absence of keratin 4 immunostaining was detected in
72/72 tumors, even when well differentiated or poorly differen-
tiated areas of OSCC were analyzed (Figure 3B–C).
Knockdown of Cofilin-1 Inhibits Cell Invasion
To clarify the role of cofilin-1 on oral cancer cell invasion, the
expression of this protein was knocked down using siRNA. Three
siRNAs with sequence complementarity to cofilin-1 transcripts
(siCofilin I, II and III) were tested in SCC-9 cells and apparently
exhibited similar functional potency. As shown in Figure 4A–C,
both Western blot and immunofluorescence analyses confirmed
down-regulation of total and p-cofilin protein expression in specific
RNAi-treated cells, but not in control cells.
In the Boyden chamber assay, which mimics invasion of cancer
cells across a basement membrane, the number of cofilin-knocked
down SCC-9 and CAL 27 cells that invaded across the Matrigel
membrane was decreased compared to cells transfected with
control siRNA (SCC-9: mean number of cells/field = 31.5 versus
173.5, Student’s t test, p,0.001; CAL 27: mean number of cells/
field = 42.3 versus 292, Student’s t test, p,0.05) (Figure 4D). The
results suggest that cofilin-1 overexpression may be important for
oral tumor cell invasion during the metastatic process.
Discussion
Oral squamous cell carcinoma is a heterogeneous disease, both
at the histopathological and molecular level, and in its response to
therapy. Accurate assignment of patients to specific subgroups is
apparently critical to predicting outcome and hence to guide
therapeutic decisions and improve survival in OSCC and other
head and neck carcinomas. An initial genetic classification model
has recently been proposed for this group of diseases by Leemans
et al. [1] using a limited number of parameters to separate classes
with different prognosis. Actually, many clinicopathological
variables and genetic/epigenetic events related to head and neck
tumorigenesis have been described and associated with reduced
survival or more-aggressive tumor behavior (reviewed by [29] and
[1]). They include traditional histopathological criteria, such as the
presence of lymph node metastases, which unfortunately is limited
in predicting outcome. A plethora of potential molecular markers
in OSCC have also been reported, although with a wide
heterogeneity in prognostic significance. The more frequently
cited are inactivation of tumor suppressor p53, p16INK4a and
PTEN (phosphatase and tensin homolog) proteins, and activation
or overexpression of cyclin D, EGFR (epidermal growth factor
receptor), MET (hepatocyte growth factor receptor) and VEGF
(vascular endothelial growth factor) [1].
In the present study, we used exploratory parameters for
classifying oral carcinomas with regard to protein expression
profile, and analyzed a large set of OSCC samples by 1-DE, 2-DE,
MS and immunodetection methods in order to contribute to the
molecular characterization of OSCC subgroups with risk of tumor
dissemination. Differential expression was evaluated using small
but lymph node metastasis-positive and large, lymph node
Protein Profile of Oral Carcinomas
PLOS ONE | www.plosone.org 6 December 2012 | Volume 7 | Issue 12 | e50517
metastasis-negative tumors, and surgical margins. The patient
group was homogeneous in relation to age and tobacco and
alcohol use, therefore, potentially presenting similar etiologic
factors.
Although divergent in number of proteins and strategies to
obtain the relative quantification values, 1-DE and 2-DE
expression patterns were consistent with each other, particularly
in the comparison between tumors and their surgical margins.
Some dissimilarity was observed between 1-DE and 2-DE
expression patterns from ‘‘more-aggressive’’ and ‘‘less-aggressive’’
tumors, likely reflecting differences between the compositions of
pools: whereas the LA group analyzed by 1-DE included only
T3N0 cases, LA group analyzed by 2-DE also included T2N0.
In general, the parameters defined by the present study for
classifying oral carcinomas revealed groups with distinctive protein
expression patterns that may be related to different tumor
behaviors. A number of proteins identified have already been
observed in OSCCs, but many others were not yet described as
deregulated in these tumors, at least to our knowledge, inter alia
asporin, ANP32A protein, a-actinin-1, four and a half LIM
domains protein 1, myozenin-1, nascent polypeptide-associated
complex subunit a, mimecan, serine/arginine-rich splicing factor
3, voltage-dependent anion-selective channel protein 1 and 14-3-3
protein b/a. Some of them are related to actin cytoskeleton,
cellular movement and cell growth or signaling. Also important
was the observation that the genes coding for several proteins
overexpressed in tumors (both MA and LA) have been mapped to
11q13 (CFL1, GSTP1, SERPINH1) and 8q23-24 (EEF1D, RPL8),
which are chromosome segments frequently amplified in head and
neck carcinomas and may be related to the progression of the
disease [30,31]. Only cofilin-1 [32–34] and glutathione S-
transferase P (or GSTP1-1) [33,35] have been previously described
in OSCC; otherwise, few studies have been done on SERPINH1,
EEF1D and RPL8 expression in head and neck carcinomas or
other neoplasms.
Concerning differences between tumors and margins, many
proteins were identified, some previously associated with OSCC,
validating our approach. As expected, those related to signaling
cascades frequently altered in cancer cells were deregulated in our
tumor samples, such as stratifin (p53 pathway), heat shock protein
b1, 14-3-3 protein b/a, Ras-related protein Rap-1A, stathmin
(EGFR, Ras and MAPKK pathway), asporin (TGFb pathway),
Figure 2. Immunodetection of cofilin-1 and p-cofilin in OSCC samples. Immunostaining for total cofilin-1 and p-cofilin in FFPE sections of (A
and B, respectively) surgical margins and (C and D, respectively) OSCC samples. Note the low positivity of total cofilin (A) and the nuclear staining for
p-cofilin (B) in the more basal layers of epithelium in margins, and (C and D, inserts) the more intense staining of tumor cell nuclei for p-cofilin than
for total cofilin. Figures and inserts = 100X and 400X magnification, respectively.
doi:10.1371/journal.pone.0050517.g002
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40S ribosomal protein S6 (mTOR pathway), heat shock protein
b1 (VEGF pathway), collagen a-1 I (WNT pathway).
Our results also included several proteins involved in keratino-
cyte differentiation and epidermis development. We noted a
keratin profile compatible with loss of differentiation in tumors:
increased expression of proteins typical of stem cells or transient
amplifying cells and loss of a keratin characteristic of differenti-
ating layers of epithelia (keratin 4) [36]. These findings shed light
on the importance of the keratinization process in oral cancer and
of identifying differentially expressed keratins or related proteins,
which may be useful for the development of new diagnostic tests
and treatments.
In 1-DE and 2-DE experiments, the absence or underexpression
of keratin 4 in tumor samples was a consistent finding, confirming
the results of several authors [37–39] and validating the strategies
used in the present study. Similar results were obtained by
Western blot in most tumors. The complete absence of keratin 4
was also observed in all tumors analyzed by immunohistochem-
istry and in a few surgical margins. Patients exhibiting keratin 4-
negative margins showed higher rates of local recurrence,
metastasis or a second primary tumor at the same anatomical
site than patients with keratin 4-positive margins. Interestingly, all
five dysplastic margins, which may represent a tumor precursor
field or the presence of residual cancer cells, were keratin 4
negative; four of the patients developed tumor relapse or a distant
metastasis. These findings are in accordance with the data of
Schaaij-Visser et al. [39] and support the recommendation that
low immunoexpression of keratin-4 in surgical margins may
qualify patients at high risk of tumor recurrence for more stringent
surveillance protocols.
With respect to tumor behavior, specific protein patterns
favoring metastasis were related to the ‘‘more-aggressive’’ group
defined by the present study. This group displayed upregulation of
proteins involved in migration, adhesion, angiogenesis, cell cycle
regulation, anti-apoptosis and epithelial to mesenchymal transi-
tion, which are consistent with a metastatic phenotype, whereas
cells of the ‘‘less-aggressive’’ group were engaged in keratinocyte
differentiation, epidermis development, inflammation and im-
mune response.
A remarkable finding of the present study was the involvement
of cofilin pathway in the aggressive phenotype, which requires
reorganization of the cytoskeleton and migratory features. Cofilin-
1, a small protein able to bind actin, has been previously shown to
be overexpressed in some tumors [40–42]. In oral carcinomas, few
studies have observed altered expression of cofilin [32–34] but no
reference about its role on oral cancer cell invasion has been
published. This protein, its isoforms and regulators play a central
role in the actin filament remodeling and are important factors
directly involved in chemotaxis, cell migration and metastasis [43].
The cofilin pathway is activated by growth factors that signal
through Rho-GTPases and several kinases, such as ROCK-1 and
Pak-1, stimulating LIM kinases (LIMKs) to phosphorylate (and
Figure 3. Immunodetection of keratin 4 expression in OSCC
samples. Immunohistochemistry analysis: pattern of keratin 4
immunostaining in (A) superficial layers of epithelium in margin
showing intense positivity in stratum corneum (A, insert); (B) absence
of keratin 4 immunostaining in nests of well differentiated and (C)
poorly differentiated areas of OSCC. Scale bar indicates 100 mm.
Western blot: (D) tumor samples (lanes 1, 3, 5, 7) and matched
margins (lanes 2, 4, 6, 8) from patients with T1N0, T4N2, T4N1 and T4N1
carcinomas, respectively; (E) Surgical margin (lane 1) and tumor samples
(lanes 2, 3, 4, 5) from patients with T4N2, T4N2, T4N2, T1N0 and T2N2,
respectively. b-actin was used as an internal control. MW, PageRulerTM
Prestained Protein Ladder.
doi:10.1371/journal.pone.0050517.g003
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thereby inactivate) cofilin-1 on Ser3. Cofilin-1 activity is also
modulated by increasing pH, by dephosphorylation through
phosphatases (slingshot or SSHs and chronophin) and by
PLCc1-dependent hydrolysis of phosphatidylinositol-4-5-bipho-
sphate (PIP2) to which it is bound at the plasma membrane
(Figure 5). Activated cofilin-1 severs ‘‘old’’ actin filaments (F-actin)
to generate globular actin (G-actin) and free actin barbed ends.
ATP-G-actin assembles into the barbed end and ATP is
hydrolyzed generating ADP-actin subunits, which are, in turn,
dissociated from the pointed end of ‘‘old’’ filaments, in a process
called treadmilling. Free G-actin monomers exchange ADP to
ATP, frequently with the help of profilin, and are again
incorporated into filaments (reviewed by [43,44] and [31]).
Cofilin competes with actin-related protein ARP2/3 [45], a
protein complex that binds to the side of F-actin and nucleates the
growth of daughter filaments at a 70u angle to the mother
filament, generating a dendritic network at the leading edge of
migratory cells [46]. The dynamic assembly at barbed ends/
Figure 4. siRNA-mediated knockdown of cofilin-1 resulted in decreased invasive ability of oral cancer cells. Western blot analysis
showed reduced levels of (A) cofilin-1 in SCC-9 cells transfected with different concentrations of siRNA (siCofilin I) for 48 h and of (B) cofilin-1 and p-
cofilin in SCC-9 cells transfected with 20 nM siCofilin I for 48 h. (C) Immunofluorescence analysis of cofilin-1 knockdown SCC-9 cells (siCofilin I) using
anti-p-cofilin antibody (green). (D) Invasion assays using Matrigel-coated filters were performed on SCC-9 and Cal 27 cells (cofilin-1 knockdown cells
and controls). Bar graph represents the mean 6 S.E. of the number cells that invaded through the Matrigel from three independent experiments
(Student’s t test, * = p,0.01).
doi:10.1371/journal.pone.0050517.g004
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disassembly at pointed ends of actin filaments and branching are
required to push the cellular membrane forward resulting in
protrusion and migration.
There are many other scaffolding activators or partners
indirectly involved in the cofilin pathway [47]. For example, 14-
3-3 proteins inhibit SHH [48], whereas RAP proteins increase the
enzymatic activity of these phosphatases through different effectors
[49], upregulating non-phosphorylated cofilin levels. Otherwise,
Hsp90 promotes stability of LIMK, which may result in increased
levels of phospho-cofilin [50]. Capping proteins interact with
barbed ends and inhibit filament assembly [51] whereas CAP1
mediates actin filament turnover [52]. Actin dynamics may also be
regulated by myosins [53], septins [54], and by tropomyosins in an
isoform-specific way [55].
In the present study, most members of the cofilin pathway
exhibited over (cofilin-1, CAP1, F-actin-capping protein a-1, HSP
90-a, tropomyosin 3) or underexpression (ARP2/3 subunit 2) in
‘‘more-aggressive’’ tumors analyzed by 1-DE, 2-DE and MS/MS,
as well in tumors compared to surgical margins (ARP2/3 subunit
2, cofilin-1, CAP1, HSP 90-a, F-actin-capping protein a-1 or
CAPZA1, Rap-1A, 14-3-3 protein b/a, profilin-1, tropomyosins).
By immunohistochemical analysis, total cofilin-1 and p-cofilin
apparently also showed higher expression in tumor than in normal
epithelium and, although the differences were not large, the results
agreed with those obtained by our proteomic experiments and by
other authors [32–34]. Unlike what was observed by 2-DE,
differences in immunoreactivity of cofilin were not evident
between MA and LA cases and the data call for validation in a
larger set of cases.
Altered cofilin/actin ratio and even slight variations in cofilin
levels may affect cell mobility. However, it is hard to have a
conclusion on the role of cofilin and its partners on the metastatic
Figure 5. Cofilin pathway. Microenvironmental stimuli signal through Rho-GTPases and their regulating kinases (ROCK1 and Pak-1), stimulating
LIMK to phosphorylate and inactivate cofilin-1. Otherwise, SSH phosphatases dephosphorylate cofilin. Rap proteins may increase the enzymatic
activity of SSHs, possibly by promoting their release from 14-3-3 proteins. Cofilin is sequestered by PIP2 and released after hydrolysis of PIP2 by
phosphorylated PLC to IP3 and DAG. The active cofilin severs ‘‘old’’ actin filaments to generate free actin barbed ends. ATP-actin assembles into these
barbed ends and ADP-actin subunits are, in turn, dissociated from the pointed end. Free actin monomers exchange ADP to ATP, frequently with the
help of profilin and CAP proteins. ARP2/3 complex binds to F-actin and nucleates the growth of daughter filaments, generating a dendritic network at
the leading edge of migratory cells. Other members of this pathway include Hsp90, which promotes stability of LIMK, and CAPZ, which interacts with
barbed ends and inhibits filament assembly. ARP = actin-related protein 2/3 complex; CAP = adenylyl cyclase-associated protein 1; CAPZ = F-actin-
capping protein subunit alpha-1; CFL = cofilin-1; F-actin = filamentous actin; DAG = diacylglycerol; G-actin = globular actin; GF = growth factor;
HSP90 = heat shock protein HSP 90-alpha; IP3 = inositoltrisphosphate; LIMK = LIM kinases; Pak-1 = serine/threonine-protein kinase PAK 1;
PIP2 = phosphatidylinositol-4-5-biphosphate; PLC = phospholipase C; RAP = Ras-related protein; ROCK-1 = Rho-associated protein kinase 1;
SSH = slingshot phosphatase.
doi:10.1371/journal.pone.0050517.g005
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behavior only from semi-quantitative analyses of their expression,
without taking into account the differences over time or between specific
subcellular compartments (reviewed by [56]).
Our results showed total cofilin-1 predominantly localized in the
cytoplasm and p-cofilin in the cytoplasm and nuclei of tumor cells.
The model by Chhabra and dos Remedios [57] explains the
presence of nuclear p–cofilin and suggests its indirect role in gene
expression. These authors proposed that cofilin transports ADP-
actin subunits into the nucleus, where the higher ATP concentra-
tion promotes the exchange of ADP for ATP. After disruption of
the cofilin-actin complex, probably by nuclear LIMK-dependent
phosphorylation of cofilin, ATP-actin monomers can self-assemble
into oligomers and influence chromatin remodeling or gene
expression (reviewed by [58]).
Cofilin-1 knockdown by siRNA significantly inhibited oral
cancer cell invasion across Matrigel in vitro. This finding agrees
with the fact that cofilin-1 is involved in the formation of
invadopodia [59], which are actin-rich membrane protrusions of
invasive cells with extracellular matrix degradation activity
[53,60]. Downregulation of cofilin expression inhibits the stability
of invadopodia [59], pointing out its role in cell invasion.
Our results indicate that the cofilin pathway is deregulated in
oral carcinomas and related to aggressive behavior. Taking into
account the definition proposed by Leemans et al. [1], CFL1 may
be considered an established cancer gene since (a) it is mapped at
11q13, a chromosome region that is amplified in head and neck
tumors and related to invasion, metastasis and decreased disease
free survival [31,61]; (b) knock down of CFL1 expression inhibits
oral cancer cell invasion in vitro (a cancer-associated phenotype),
which hints at an oncogenic function; and finally, (c) CFL1 protein
is activated by EGFR and its effectors [43], a signaling pathway
with several established cancer genes related to oral cancer, such
as EGFR itself, PTEN and CCND1 [1].
Conclusion
To our knowledge, this is the first proteomic study of oral
carcinomas that compares small but lymph node metastasis-
positive and large, lymph node metastasis-negative tumors. We
observed that these criteria separate distinctive protein expression
patterns and that the tumor size parameter might improve the
detection of proteins associated with an aggressive behavior.
Besides the identification of several proteins not yet described as
deregulated in oral cancer, the present study demonstrated for the
first time the role of cofilin-1 in modulating OSCC cell invasion,
adding new data that may be useful for predicting aggressive
phenotype in OSCC.
Supporting Information
Figure S1 Partial 2-DE gel images of proteins from
‘‘more-aggressive’’ (T1-2N+) OSCC tumors and surgical
margins. Myosin light chain 1/3, skeletal muscle isoform
(MLC1/MLC3); beta-globin (HBB); carbonic anhydrase 3 (CA-
III); creatine kinase M-type (M-CK); keratin 4 (CK-4); gamma-
actin (ACTG); myoglobin (MB); myosin light chain 3 (MYL3);
myosin regulatory light chain 2, skeletal muscle isoform (MLC2B);
myosin regulatory light chain 2, ventricular/cardiac muscle
isoform (MLC-2v); tropomyosin-1 (TPM1); tropomyosin-2
(TPM2); tropomyosin-3 (TPM3); alpha-enolase (ENO1); cofilin-1
(CFL1); cyclophilin A (PPIase A); keratin 19 (CK-19); glutathione
S-transferase P (GSTP1-1); heat shock 27 kDa (HSP 27);
calgranulin-B (S100-A9); serum albumin (ALB); stratifin (SFN);
superoxide dismutase [Cu-Zn] (SOD1); tropomyosin-4 (TPM4);
vimentin (VIM). Tumors and matched surgical margins from
tongue (C02) and floor of mouth (C04).
(TIF)
Figure S2 Partial 2-DE gel images of proteins from
‘‘less-aggressive’’ (T2-3N0) OSCC tumors and surgical
margins. Myosin light chain 1/3, skeletal muscle isoform
(MLC1/MLC3); annexin A1 (ANXA1); carbonic anhydrase 3
(CA-III); creatine kinase M-type (M-CK); myoglobin (MB); myosin
light chain 3 (MYL3); myosin regulatory light chain 2, skeletal
muscle isoform (MLC2B); myosin regulatory light chain 2,
ventricular/cardiac muscle isoform (MLC-2v); tropomyosin-1
(TPM1); tropomyosin-2 (TPM2); tropomyosin-3 (TPM3); troponin
T, slow skeletal muscle (TnTs); alpha-enolase (ENO1); cofilin-1
(CFL1); cyclophilin A (PPIase A); keratin 19 (CK-19); galectin-7
(Gal-7); heat shock 27 kDa (HSP 27); stratifin (SFN); tropomyosin-
4 (TPM4). Tumors and matched surgical margins from tongue
(C02) and floor of mouth (C04).
(TIF)
Figure S3 Partial 2-DE gel images of proteins from
‘‘more-aggressive’’ (T1-2N+) and ‘‘less-aggressive’’ (T2-
3N0) OSCC tumors. Alpha-enolase (ENO1); annexin A2
(ANXA2); cofilin-1 (CFL1); glutathione S-transferase P (GSTP1-
1); keratin 19 (CK-19); myoglobin (MB); stratifin (SFN); superox-
ide dismutase (SOD1). Tumor samples from tongue (C02) and
floor of mouth (C04).
(TIF)
Table S1 Clinicopathological features of 144 patients
with OSCC and techniques used to analyze the samples.
T= tumor; Ma= surgical margin; F= female; M=male; P or
Neg= positive or negative exposition to tobacco/alcohol, respec-
tively, but consumption time is indeterminate; 1-DE=one-
dimensional gel electrophoresis; 2-DE= two-dimensional gel
electrophoresis; WB=Western blot; IH= immunohistochemistry;
NA=not available.
(DOC)
Table S2 Pools organized into groups according to TNM
system. 1-DE=one-dimensional gel electrophoresis; 2-
DE= two-dimensional gel electrophoresis.
(DOC)
Table S3 Protein identification in ‘‘more-aggressive’’
(MA), ‘‘less-aggressive’’ (LA) tumor groups and their
surgical margins (SM) by 1-DE and Scaffold software
according to quantitative value. Proteins with a fold change
of at least 1.5 were considered with differential abundance
between the groups.
(PDF)
Table S4 Differentially expressed proteins identified by
2-DE followed by mass spectrometry analysis in ‘‘more-
aggressive’’ (MA), ‘‘less-aggressive’’ (LA) tumor groups
and their surgical margins (SM). MA/SM, LA/SM and
MA/LA abundance ratio.
(DOC)
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